New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
06:10 EDTAZN, DTVStocks with implied volatility below IV index mean; AZN DTV
Stocks with implied volatility below IV index mean; AstraZeneca (AZN) 25, DirecTV (DTV) 14.
News For AZN;DTV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
05:25 EDTAZNAstraZeneca enters co-development and commercialization with Innate Pharma
Subscribe for More Information
July 6, 2015
15:32 EDTDTVFCC decision on AT&T, DirecTV deal still 'few days' away, CTFN says
The Federal Communications Commission is expected to clear AT&T's (T) deal for DirecTV (DTV), but will be a “few more days” before the review is completed and the conditions that will be imposed remain unclear, according to CTFN, citing a source close to the matter. Reference Link
July 2, 2015
10:00 EDTAZNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Outperform from Market Perform at Cowen... Acadia Realty Trust (AKR) upgraded to Buy from Neutral at Citi... Alliance Resource Partners (ARLP) upgraded to Buy from Hold at Deutsche Bank... ArcBest (ARCB) upgraded to Peer Perform from Underperform at Wolfe Research... AstraZeneca (AZN) upgraded to Buy from Hold at Berenberg... ConAgra (CAG) upgraded to Overweight from Equal Weight at Morgan Stanley... DuPont Fabros (DFT) upgraded to Buy from Neutral at Citi... EastGroup Properties (EGP) upgraded to Buy from Neutral at Citi... Galaxy Entertainment (GXYEY) upgraded to Hold from Sell at Deutsche Bank... GrubHub (GRUB) upgraded to Outperform from Sector Perform at RBC Capital... HealthSouth (HLS) upgraded to Outperform from Market Perform at JMP Securities... IGM Financial (IGIFF) upgraded to Sector Performer from Underperformer at CIBC... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Kimco Realty (KIM) upgraded to Buy from Neutral at Citi... Kosmos (KOS) upgraded to Outperform at BMO Capital... MGM China (MCHVF) upgraded to Hold from Sell at Deutsche Bank... Regal Entertainment (RGC) upgraded to Neutral from Sell at B. Riley... SL Green Realty (SLG) upgraded to Buy from Neutral at Citi... SQM (SQM) upgraded to Buy from Hold at HSBC... Sands China (SCHYY) upgraded to Hold from Sell at Deutsche Bank... Terex (TEX) upgraded to Neutral from Underperform at BofA/Merrill... United Community Banks (UCBI) upgraded to Outperform from Market Perform at Raymond James... Weingarten Realty (WRI) upgraded to Buy from Neutral at Citi... Willis Group (WSH) upgraded to Neutral from Sell at Goldman... Wynn Macau (WYNMF) upgraded to Hold from Sell at Deutsche Bank.
05:30 EDTAZNAstraZeneca upgraded to Buy from Hold at Berenberg
Subscribe for More Information
July 1, 2015
15:23 EDTDTVDISH's Ergen awaits AT&T-DirecTV approval before more T-Mobile talks, FBN says
Subscribe for More Information
13:57 EDTDTVAT&T-DirecTV deal set to be cleared by U.S. antitrust officials, Bloomberg says
AT&T’s (T) proposed $48.5B deal to buy DirecTV (DTV) is slated to be cleared by U.S. antitrust officials without any conditions, Bloomberg reports, citing a personal familiar with the deliberations by the Justice Department. The merger still requires approval from the FCC, which may demand concessions such as following net neutrality rules, the report says. Reference Link
June 30, 2015
18:11 EDTDTVAT&T, DirecTV merger may get U.S. approval next week, Reuters says
Subscribe for More Information
10:19 EDTAZNAstraZeneca, Eolas Therapeutics partner on EORA program for smoking cessation
Eolas Therapeutics said that is has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics grant from the National Institutes of Health for the development of the program from the preclinical stage through phase I clinical trials. The total deal potential is in excess of $145M. This includes upfront, clinical and regulatory milestone payments. Additionally, Eolas is eligible to receive royalties on commercial sales.
June 29, 2015
17:25 EDTDTVAT&T, DirecTV elect to further extend merger termination date
Subscribe for More Information
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
15:32 EDTDTVDoubtful that FCC votes on AT&T, DirecTV deal this week, CTFN says
Sources said it is looking "increasingly doubtful" that the FCC will vote this week on the proposed merger between AT&T (T) and DirecTV (DTV), according to CTFinancialNews. Reference Link
June 25, 2015
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
June 24, 2015
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
June 23, 2015
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
05:41 EDTDTVAT&T upgraded to Buy from Neutral at UBS
UBS analyst John Hodulik upgraded AT&T (T) to Buy citing an attractive valuation at current share levels. Hodulik expects the phone giant's core domestic wireless business to show "meaningful improvement" in Q2. He also thinks financial benefits from the DirecTV (DTV) acquisition are being underappreciated by the market. Hodulik raised his price target for AT&T shares to $42 from $34. The stock was also upgraded this morning by Barclays analyst Amir Rozwadowski. AT&T shares closed yesterday up 5c to $35.04.
05:35 EDTDTVAT&T upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Amir Rozwadowski upgraded AT&T (T) to Overweight saying earnings estimates should move higher following the close of the DirecTV (DTV) acquisition. After visiting AT&T's headquarters, Rozwadowski believes synergies from the deal are "too material to ignore." He raised his price target for AT&T shares to $39 from $34. The stock closed yesterday up 5c to $35.04.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use